PTGS2 and neoplasm: In addition to developing a promising anti-tumour strategy by targeting the COX-2 signalling pathway, increasing evidence, including our previous studies, links the inhibition of COX-2 expression to anti-HCV activity at present [14], [15], [16],[17].